Vocimagene amiretrorepvec

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Vocimagene amiretrorepvec
DrugBank Accession Number
DB15331
Background

Vocimagene amiretrorepvec is under investigation in clinical trial NCT02576665 (A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)).

Type
Biotech
Groups
Investigational
Synonyms
  • Vocimagene amiretrorepvec
External IDs
  • TOCA 511

Pharmacology

Indication

Not Available

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
DC4WO3WA4Q
CAS number
1300724-82-6

References

General References
Not Available
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2, 3TerminatedTreatmentAnaplastic Astrocytoma (AA) / Glioblastoma Multiforme (GBM)1
2, 3WithdrawnTreatmentAnaplastic Astrocytoma (AA) / Glioblastomas / Oligodendrogliomas / Supratentorial Glioblastoma1
1CompletedTreatmentAnaplastic Astrocytoma (AA) / Anaplastic Oligoastrocytoma / Anaplastic Oligodendroglioma (AO) / Glioblastoma Multiforme (GBM)2
1CompletedTreatmentAnaplastic Astrocytoma (AA) / Anaplastic Oligoastrocytoma / Anaplastic Oligodendroglioma (AO) / Glioblastomas1
1TerminatedTreatmentAstrocytomas / Glioblastoma Multiforme (GBM) / Gliomas, Malignant1
1TerminatedTreatmentCancer, Bladder / Colorectal, Cancer / Head and Neck Carcinoma / IDH1 Mutated or MGMT Methylated Recurrent HGG (Not Recruiting) / IDH1 Mutated Solid Tumors / Malignant Lymphomas / Malignant Neoplasm of Pancreas / Melanomas / Non-Small Cell Lung Carcinoma (NSCLC) / Ovarian Cancer / Sarcomas / Triple Negative Breast Cancer (TNBC)1
1WithdrawnTreatmentCancer, Bladder1
1WithdrawnTreatmentNewly Diagnosed High Grade Glioma (HGG)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on May 20, 2019 15:15 / Updated on February 21, 2021 18:55